Head-to-head · WeighScore
Omada Health vs PauseRX
The verdict
PauseRX takes it — 68.5/100 to 55.6/100.
PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Omada Health | PauseRX |
|---|---|---|
| WeighScore | 55.6/100 | 68.5/100 |
| Grade | C | C |
| Scorecard rank | #435 | #147 |
| Semaglutide | Not disclosed | $199/mo |
| Tirzepatide | Not disclosed | $249/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Graded #147 · C
Strengths
- Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
- Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
- Publishes the FDA compounded-medication disclaimer
- Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
- Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation
Where it loses points
- States served not listed — site claims nationwide, but you must contact support to confirm availability
- Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
- No named medical director (Beluga Health is the network, not a named MD)
- LegitScript certification number not shown — badge only, so no direct lookup
- Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.